US20020159953A1 - Method to diagnose and monitor cellular immune deficiencies - Google Patents
Method to diagnose and monitor cellular immune deficiencies Download PDFInfo
- Publication number
- US20020159953A1 US20020159953A1 US10/137,769 US13776902A US2002159953A1 US 20020159953 A1 US20020159953 A1 US 20020159953A1 US 13776902 A US13776902 A US 13776902A US 2002159953 A1 US2002159953 A1 US 2002159953A1
- Authority
- US
- United States
- Prior art keywords
- set forth
- skin test
- mitogen
- ncm
- immunotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000001413 cellular effect Effects 0.000 title description 13
- 230000007812 deficiency Effects 0.000 title description 13
- 238000012360 testing method Methods 0.000 claims abstract description 80
- 108010047620 Phytohemagglutinins Proteins 0.000 claims abstract description 42
- 230000001885 phytohemagglutinin Effects 0.000 claims abstract description 42
- 238000009169 immunotherapy Methods 0.000 claims abstract description 35
- 230000004044 response Effects 0.000 claims abstract description 34
- 239000003226 mitogen Substances 0.000 claims abstract description 31
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 29
- 102000004127 Cytokines Human genes 0.000 claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 claims abstract description 22
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 15
- 108010062580 Concanavalin A Proteins 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 13
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 102000036639 antigens Human genes 0.000 claims abstract description 12
- 108091007433 antigens Proteins 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000012544 monitoring process Methods 0.000 claims abstract description 10
- 235000009074 Phytolacca americana Nutrition 0.000 claims abstract description 8
- 241001275115 Phytolacca bogotensis Species 0.000 claims abstract description 8
- 238000004458 analytical method Methods 0.000 claims abstract description 7
- 230000024932 T cell mediated immunity Effects 0.000 claims abstract description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 28
- 206010025327 Lymphopenia Diseases 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 238000004166 bioassay Methods 0.000 claims description 6
- 238000004820 blood count Methods 0.000 claims description 6
- 230000000899 immune system response Effects 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 abstract description 12
- 210000001616 monocyte Anatomy 0.000 abstract description 12
- 238000006243 chemical reaction Methods 0.000 abstract description 7
- 210000000987 immune system Anatomy 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 4
- 230000002500 effect on skin Effects 0.000 abstract description 4
- 230000008595 infiltration Effects 0.000 abstract description 4
- 238000001764 infiltration Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 9
- 230000005951 type IV hypersensitivity Effects 0.000 description 9
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 230000007969 cellular immunity Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000010536 head and neck cancer Diseases 0.000 description 5
- 208000014829 head and neck neoplasm Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000003514 immunorestorative effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 239000001973 thioglycolate broth Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5055—Cells of the immune system involving macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
Definitions
- T-lymphocyte functions proliferation, cytokine production, cytotoxicity, help and suppression
- CMI cellular immunity
- DTH delayed-type hypersensitivity
- DTH is frequently tested clinically with the use of skin tests to recall antigens such as purified protein derivative (PPD), tetanus toxoid, candida and other antigens.
- PPD purified protein derivative
- tetanus toxoid tetanus toxoid
- candida candida
- DTH is frequently tested clinically with the use of skin tests to recall antigens such as purified protein derivative (PPD), tetanus toxoid, candida and other antigens.
- PPD purified protein derivative
- tetanus toxoid tetanus toxoid
- candida candida and other antigens.
- T-lymphocyte (CD3, CD11) and subsets (CD4, CD8) counts using cytofluorometry (FACS) are now performed frequently on patients with HIV infection and are considered to be an important prognostic predictor of the outcome of this disease.
- FACS analyses of T-lymphocyte and subsets are expensive tests and generally only available in the industrialized countries.
- CBC complete blood count
- WBC white blood cell count
- B-lymphocytes B-lymphocytes
- T-lymphocytopenia as occurs in cancer, cancer therapy, irradiation, and HIV infection generally reflects greater early losses of CD4 than CD8 cells.
- a lymphocyte count and infer with a great degree of accuracy that if it is significantly low (i.e. ⁇ 1500 mm 3 ) then T-lymphocytopenia is present and cellular immunity may be impaired.
- T-lymphocyte function A variety of in vitro tests of T-lymphocyte function have been developed including lymphoproliferative responses to mitogens like phytohemagglutinin (PHA) or Concanavalin A (Con A), interleukin (IL) production like IL-2 and gamma interferon (IFN- ⁇ ), cytotoxicity for target cells, etc. These tests are expensive, cumbersome, and performed only at academic centers where appropriate research laboratories are present.
- PHA phytohemagglutinin
- Con A Concanavalin A
- IL interleukin
- IFN- ⁇ gamma interferon
- NCM natural cytokine mixture
- a method and kit for determining candidates for immunotherapy, for monitoring the effect of immunotherapy and analysis of cell mediated immunity functionality in a patient includes performing two intracutaneous skin tests and reading the skin test after twenty-four hours.
- One skin test is the administration of a mitogen such as phytohemagglutinin (PHA), concanavalin A (ConA), pokeweed antigen (PWA) and other mitogens as known in the art.
- PHA phytohemagglutinin
- ConA concanavalin A
- PWA pokeweed antigen
- the PHA skin test responses reflects the ability of the T-lymphocytes which are present to react to PHA and to release cytokines like IL-2 and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction which is observed in the skin test characteristic of the afferent limb response of the immune system.
- the NCM (mitogen-stimulated natural cytokine mixture) skin test reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response.
- the kit contains the appropriate mitogen and NCM to be used in the skin tests.
- the present invention provides a method to monitor patients with cellular immune deficiency by the steps of determining the result of intracutaneous skin tests with a mitogen such as PHA and with natural cytokine mixture (NCM) and the result of blood lymphocyte counts (with or without T-lymphocyte and subset enumeration) to yield a composite “three-dimensional view” of CMI including T-lymphocyte number and function (afferent limb) and cytokine production and action on monocytes and macrophages (efferent limb)
- a mitogen such as PHA and with natural cytokine mixture (NCM)
- NCM natural cytokine mixture
- FIG. 1 is a graph showing the correlation between lymphocyte count and PHA skin test response in cancer patients
- FIG. 2 is a graph showing the correlation between lymphocyte count and NCM skin test response in patients with squamous cell head and neck cancer (H&N SCC);
- FIG. 3 is a graph showing the correlation between PHA and NCM skin test response in patients with squamous cell head and neck cancer (H&N SCC).
- FIG. 4 is a graph showing the correlation between lymphocyte count and PHA skin test response in patients with squamous cell head and neck cancer (H&N SCC).
- the present invention provides a method and kit for determining candidates for immunotherapy and for monitoring the effect of immunotherapy in a patient undergoing immunotherapy (see Table 1).
- Patients who need to be selected as candidates for immunotherapy for example are patients who have cancer.
- Patients who need to be monitored for example are patients who are undergoing immunotherapy for cancer. It is useful to know if the patient is responding or has the potential for responding no matter the white blood cell count. Additionally, the method of the present invention allows the selection of patients who are good candidates for immunotherapy amount those patients who need immunotherapy.
- the method includes performing two intracutaneous skin tests and reading the skin test after twenty-four hours.
- One skin test is the administration of a mitogen such as phytohemagglutinin (PHA), concanavalin A (ConA) pokeweed antigen (PWA) and other mitogens as known in the art.
- PHA phytohemagglutinin
- ConA concanavalin A
- PWA pokeweed antigen
- the dose administered is between the range of 0.5 to 1.0 ⁇ g.
- Example 2 herein there is a correlation with responsiveness in the skin tests to immunotherapy response, particularly to immunotherapy with NCM.
- the PHA skin test responses reflect the ability of the T-lymphocytes which are present, to react to PHA and to release cytokines like IL-2, IFN K, etc. and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction which is observed in the skin test characteristic of the afferent limb response of the immune system.
- the NCM (mitogen-stimulated natural cytokine mixture) skin test reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response. The two responses allow the determination of whether the afferent or efferent or both limbs of the immune response are affected and can then be correlated with T-cell number.
- the functionality of the T-cells present can be determined by this method and it will have an effect on the outcome and design of immunotherapy.
- the present invention allows the monitoring during immunotherapy for changes to determine if the course of treatment is having an effect and in which direction. It further allows for monitoring that the immunotherapy is not causing changes in the responsiveness of the T-cells present in the patient. Further, by knowing whether both the efferent and afferent limbs of the immune system are functional, good candidates for immunotherapy can be selected.
- the kit contains the appropriate mitogen and NCM at the required concentrations to be used in the skin tests. Additionally, the kit will contain the materials including syringes and needles to administer the skin test as well as control solutions that do not contain the mitogen or NCM.
- the method of the present invention and kit also provide an analysis of the functionality of cell mediated immunity in a patient needing such an analysis.
- two intracutaneous skin tests are administered and read after twenty-four hours.
- the two skin tests are the NDM and mitogen skin tests.
- a white blood cell count with the percent lymphocytes determined is also performed.
- the results of a lymphocyte count of ⁇ 1500 mm 3 indicate a T-lymphocytopenia.
- the further analysis then allows the determination of how the T-cells that are present are functioning, that is, are only the afferent or efferent or both limbs of the immune system functional.
- the present invention provides a method to monitor patients with cellular immune deficiency by the steps of determining the result of intracutaneous skin tests with a mitogen such as PHA and with natural cytokine mixture (NCM) and the result of blood lymphocyte counts (with or without T-lymphocyte and subset enumeration) to yield a composite “three-dimensional view” of CMI including T-lymphocyte number and function (afferent limb) and cytokine production and action on monocytes and macrophages (efferent limb).
- a mitogen such as PHA and with natural cytokine mixture (NCM)
- NCM natural cytokine mixture
- Immunoassays In general, ELISAs are one immunoassays employed to assess a specimen as needed. ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays.
- immunoassays such as radioimmunoassays (RIA)
- RIA radioimmunoassays
- Available immunoassays are extensively described in the patent and scientific literature. See, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,,521 as well as Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Springs Harbor, New York, 1989.
- Intracutaneous skin tests are performed and evaluated as is generally known in the art. Briefly, sterile test solutions are prepared and administer generally using 25- or 27-gauge needles. The largest dimensions of both erythema and induration are measured with a ruler, in the method of the present invention at 24 hours. The inflammatory infiltrate that accumulates at the site and accompanying edema result in the induration of the skin and the diameter of this reaction ia an index of the response. Induration of 5 mm or more in diameter is the generally accepted criterion of a positive response, strong positive (major) responses can be grater than 1 centimeter. In general a negative reaction will provide a response similar to the control (no antigen) site.
- NCM Natural Cytokine Mixture
- the buffy coat white cells of human blood from multiple HIV-negative hepatitis virus-negative donors is collected.
- animals are the cell source for veterinary uses.
- the cells from the donors are pooled and layered on ficoll hypaque gradients (Pharmacia) to yield lymphocytes free of neutrophils and erythrocytes.
- Pharmacia ficoll hypaque gradients
- the lymphocytes are washed and distributed in X vivo-10 media (Whittaker Bioproducts) to flasks (MicroCELLectorTM T-25 Cell Culture Flasks) in which are immobilized stimulants, i.e. mitogens, and in a preferred embodiment of the present invention PHA.
- immobilized stimulants i.e. mitogens
- PHA i.e. mitogens
- PHA pokeweed antigen
- OKT-3 can be used.
- X vivo-15 and X vivo-20 media can be used.
- the immobilization process for the stimulants is as described by the manufacturer for immobilizing various substances for panning procedures, i.e. separating cells, in the flasks.
- the cells are incubated for 24-48 hours in X vivo-10 media with 80 ⁇ g/ml ciprofloxacin (Miles Lab) at 37° in a CO 2 /air incubator.
- X vivo-10 media 80 ⁇ g/ml ciprofloxacin (Miles Lab) at 37° in a CO 2 /air incubator.
- RPMI 1640 media is used (Webb et al. 1973).
- HSA Human serum albumin
- HSA Human serum albumin
- the supernatants are stored at 4° C. to ⁇ 70° C.
- the pooled supernatants are characterized by measuring the cytokine content by bioassay for IL-2 and ELISAs for the remaining interleukins IL-1-IL-15, CSFs, TNFs, and IFNs.
- bioassay for IL-2 and ELISAs for the remaining interleukins IL-1-IL-15, CSFs, TNFs, and IFNs.
- the following assays and kits are used in a preferred embodiment: INF- ⁇ ELISA (ENDOGEN), IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, GM-CSF, G-CSF and TNF-A ELISAs (R&D Systems).
- the IL-2 bioassay is by the method of Gillis et al. (Gillis et al.
- T Cell Growth Factor Parameters of Production and a Quantitive Microassay for Activity
- J. Immunol. 120:2027-2032, 1978
- IL-2 Schottriglycerol-2
- Sterility is tested by culture in thioglycolate broth and endotoxin measured by limulus lysate assay as is known in the art.
- Each supernatant is standardized for IL-2 content either by concentration or amount administered.
- the NCM is standardized to have an equivalence of 15 Units of IL-2 by bioassay in 0.1 ml of the supernatant.
- DNA and virus exclusion when used, employ such techniques as ultrafiltration, column chromatography, virasol, ethanol fractionation, polyethylene glycol/bentonite precipitation, gamma irradiation, and/or solvent/detergent treatment as has been used for intravenous gamma globulin and monoclonal antibodies (e.g. IGIV News Update brochure).
- H&N SCC patients were analyzed for PHA and NCM skin tests and lymphocyte counts and little or no correlations were observed (FIGS. 2, 4). These data indicate that each test is looking at a different component of the CMI/DTH defects in H&N SC cancer as would be expected:
- T-lymphocyte counts reflect T-lymphocyte number and indirectly the pool size
- PHA skin test responses reflects the ability of these T-lymphocytes which are present to react to PHA and to release cytokines like IL-2, IFN K, etc. and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction, and
- the NCM mitogen-stimulated natural cytokine mixture
- the NCM reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response.
- NCM+ patients on protocol eight were lymphocytopenic ( ⁇ 1500 mm 3 ) with a mean count of 1247 ⁇ 92. All but one of these patients showed an increase in lymphocytes to a mean of 1866 ⁇ 172 (p ⁇ 0.01 by paired student T-test). Of the eight NCM negative patients, five were lymphocytopenic (mean 1391 ⁇ 37) and only one showed an increase by Chi square analysis (TABLE 3). Thus, the NCM skin test also predicts the immunorestorative effect of NCM on patients with low lymphocyte counts.
- NCM has been associated with an increase in the PHA skin test.
- NCM therapy has been associated with an increase in the NCM skin test.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Ecology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method and kit for determining candidates for immunotherapy, for monitoring the effect of immunotherapy and analysis of cell mediated immunity functionality in a patient who needs immunotherapy is provided. The method includes performing two intracutaneous skin tests and reading the skin test after twenty-four hours. One skin test is the administration of a mitogen such as phytohemagglutinin (PHA), concanavalin A (ConA), pokeweed antigen (PWA) and other mitogens as known in the art. The PHA skin test responses reflect the ability of the T-lymphocytes which are present to react to PHA and to release cytokines like IL-2 and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction which is observed in the skin test characteristic of the afferent limb response of the immune system. The NCM (mitogen-stimulated natural cytokine mixture) skin test reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response.
Description
- 1. Field of the Invention
- A method and kit to monitor and for diagnosis of cellular immune deficiencies.
- 2. Description of Related Art
- A variety of clinical tests have been used to evaluate cellular immune responses in diseases involving congenital or acquired cellular immune deficiency (see in general Stites et al. (eds), Basic and Clinical Immunology (8th Edition), Appleton & Lange, Norwalk, Conn. (1994)). Primary cellular immune deficiency such as DiGeorge Syndrome is associated with the lack of a thymus and thus T-lymphocytes in blood and tissues. Secondary cellular immune deficiencies occur in a variety of conditions (see Table I), perhaps most notably in cancer and human immunodeficiency virus (HIV) infections. In these diseases, impairment of T-lymphocyte functions (proliferation, cytokine production, cytotoxicity, help and suppression) are often manifest early and followed by a loss of T-lymphocytes in blood (lymphocytopenia) and lymphoid tissues. Often, monocyte/macrophage defects occur which may contribute to impairment of cellular immunity (CMI) also referred to as delayed-type hypersensitivity (DTH).
- DTH is frequently tested clinically with the use of skin tests to recall antigens such as purified protein derivative (PPD), tetanus toxoid, candida and other antigens. These tests are not generally standardized. One test device, the Merieux Multitest device, has been employed; however, it is expensive (>$90/test) and insensitive and prone to false negative reaction. Perhaps the most useful test historically, particularly in cancer, has been primary sensitization with a new antigen like dinitrochlorobenzene (DNCB), followed by a challenge. The DNCB skin test has been useful to predict survival in patients with human cancer i.e. patients with a good response to DNCB will live longer and have better survival rates with conventional therapy then those who have a poor response. It is, however, difficult to perform and there are concerns regarding possible toxicity, and cross-sensitizing (Stites, et al, ibid at page 196) and is thus seldom used.
- T-lymphocyte (CD3, CD11) and subsets (CD4, CD8) counts using cytofluorometry (FACS) are now performed frequently on patients with HIV infection and are considered to be an important prognostic predictor of the outcome of this disease. FACS analyses of T-lymphocyte and subsets are expensive tests and generally only available in the industrialized countries.
- Historically, physicians have performed routinely a complete blood count (CBC) and differential. With these data the white blood cell count (WBC) and the percent of lymphocytes are determined; however, in general, the WBC and percent lymphocyte are not multiplied to yield a lymphocyte count (normally around 2000 mm3). Further, approximately 20% of circulating lymphocytes are B-lymphocytes and these values have been determined to vary little throughout life and during various disease. Thus, physicians are generally unaware that lymphocyte counts of <1500 mm3 reflect mainly T-lymphocytopenia approaching clinical significance.
- Where analyzed, T-lymphocytopenia as occurs in cancer, cancer therapy, irradiation, and HIV infection generally reflects greater early losses of CD4 than CD8 cells. Thus, one can determine a lymphocyte count and infer with a great degree of accuracy that if it is significantly low (i.e. <1500 mm3) then T-lymphocytopenia is present and cellular immunity may be impaired.
- A variety of in vitro tests of T-lymphocyte function have been developed including lymphoproliferative responses to mitogens like phytohemagglutinin (PHA) or Concanavalin A (Con A), interleukin (IL) production like IL-2 and gamma interferon (IFN-γ), cytotoxicity for target cells, etc. These tests are expensive, cumbersome, and performed only at academic centers where appropriate research laboratories are present.
- Clinical medicine needs not only new approaches to the diagnosis of cellular immune deficiency but also to monitor the effect of immunotherapy. Historically, natural killer (NK) cells have been employed to monitor the effect of recombinant interferon alpha (rIFN-α) therapy, yet in fact clinical responses have not correlated with NK cell number or activity. T-lymphocyte counts have responded to intravenous therapy with high dose rIL-2; however the response is little or not at all with subcutaneous therapy with low doses of rIL-2. Thus, new approaches are needed for the diagnosis and monitoring of CMI in human patients with cancer and other diseases in which cellular immune deficiencies are common.
- The use of a natural cytokine mixture (NCM) has proven effective in the treatment of cellular immune deficiency relating to age and stress (U.S. Pat. No. 5,632,983).
- The clinical application of this NCM in the immunotherapy of four patients with squamous cell head and neck cancer (H&N SCC) induced significant immune regressions in three of four patients (Hadden et al. “Interleukins and Contrasuppression Induce Immune Regression of Head and Neck Cancer”,Int. Arch. Otolaryngol., 120:395-403, 1994). In this study, a DTH intracutaneous skin test was performed. Three patients who were lymphocytopenic responded to NCM therapy with increased T-lymphocyte counts, including the skin test negative patient; thus, the skin test did not appear to predict the immunorestorative response to NCM.
- It would be useful to effectively analyze DTH in the patient with cellular immune deficiency and to monitor the effect of immunotherapy designed to correct this deficiency.
- According to the present invention, a method and kit for determining candidates for immunotherapy, for monitoring the effect of immunotherapy and analysis of cell mediated immunity functionality in a patient is provided. The method includes performing two intracutaneous skin tests and reading the skin test after twenty-four hours. One skin test is the administration of a mitogen such as phytohemagglutinin (PHA), concanavalin A (ConA), pokeweed antigen (PWA) and other mitogens as known in the art. The PHA skin test responses reflects the ability of the T-lymphocytes which are present to react to PHA and to release cytokines like IL-2 and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction which is observed in the skin test characteristic of the afferent limb response of the immune system. The NCM (mitogen-stimulated natural cytokine mixture) skin test reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response.
- The kit contains the appropriate mitogen and NCM to be used in the skin tests.
- In other words, the present invention provides a method to monitor patients with cellular immune deficiency by the steps of determining the result of intracutaneous skin tests with a mitogen such as PHA and with natural cytokine mixture (NCM) and the result of blood lymphocyte counts (with or without T-lymphocyte and subset enumeration) to yield a composite “three-dimensional view” of CMI including T-lymphocyte number and function (afferent limb) and cytokine production and action on monocytes and macrophages (efferent limb)
- Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:
- FIG. 1 is a graph showing the correlation between lymphocyte count and PHA skin test response in cancer patients;
- FIG. 2 is a graph showing the correlation between lymphocyte count and NCM skin test response in patients with squamous cell head and neck cancer (H&N SCC);
- FIG. 3 is a graph showing the correlation between PHA and NCM skin test response in patients with squamous cell head and neck cancer (H&N SCC); and
- FIG. 4 is a graph showing the correlation between lymphocyte count and PHA skin test response in patients with squamous cell head and neck cancer (H&N SCC).
- The present invention provides a method and kit for determining candidates for immunotherapy and for monitoring the effect of immunotherapy in a patient undergoing immunotherapy (see Table 1). Patients who need to be selected as candidates for immunotherapy for example are patients who have cancer. Patients who need to be monitored for example are patients who are undergoing immunotherapy for cancer. It is useful to know if the patient is responding or has the potential for responding no matter the white blood cell count. Additionally, the method of the present invention allows the selection of patients who are good candidates for immunotherapy amount those patients who need immunotherapy.
- The method includes performing two intracutaneous skin tests and reading the skin test after twenty-four hours. One skin test is the administration of a mitogen such as phytohemagglutinin (PHA), concanavalin A (ConA) pokeweed antigen (PWA) and other mitogens as known in the art. As shown in the exemplar herein, when PHA is used the dose administered is between the range of 0.5 to 1.0 μg. As shown in Example 2 herein, there is a correlation with responsiveness in the skin tests to immunotherapy response, particularly to immunotherapy with NCM.
- The PHA skin test responses reflect the ability of the T-lymphocytes which are present, to react to PHA and to release cytokines like IL-2, IFN K, etc. and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction which is observed in the skin test characteristic of the afferent limb response of the immune system. The NCM (mitogen-stimulated natural cytokine mixture) skin test reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response. The two responses allow the determination of whether the afferent or efferent or both limbs of the immune response are affected and can then be correlated with T-cell number. In other words, the functionality of the T-cells present can be determined by this method and it will have an effect on the outcome and design of immunotherapy. The present invention allows the monitoring during immunotherapy for changes to determine if the course of treatment is having an effect and in which direction. It further allows for monitoring that the immunotherapy is not causing changes in the responsiveness of the T-cells present in the patient. Further, by knowing whether both the efferent and afferent limbs of the immune system are functional, good candidates for immunotherapy can be selected.
- The kit contains the appropriate mitogen and NCM at the required concentrations to be used in the skin tests. Additionally, the kit will contain the materials including syringes and needles to administer the skin test as well as control solutions that do not contain the mitogen or NCM.
- The method of the present invention and kit also provide an analysis of the functionality of cell mediated immunity in a patient needing such an analysis. As described herein above, two intracutaneous skin tests are administered and read after twenty-four hours. The two skin tests are the NDM and mitogen skin tests. In addition a white blood cell count with the percent lymphocytes determined is also performed. The results of a lymphocyte count of <1500 mm3 indicate a T-lymphocytopenia. The further analysis then allows the determination of how the T-cells that are present are functioning, that is, are only the afferent or efferent or both limbs of the immune system functional. Patients who respond positively to the PHA intracutaneous skin tests have a functional afferent immune system response and patients who respond positively to the NCM intracutaneous skin tests have a functional efferent immune system response such that the functionality of the T-cells that are present can be determined.
- In summary, the present invention provides a method to monitor patients with cellular immune deficiency by the steps of determining the result of intracutaneous skin tests with a mitogen such as PHA and with natural cytokine mixture (NCM) and the result of blood lymphocyte counts (with or without T-lymphocyte and subset enumeration) to yield a composite “three-dimensional view” of CMI including T-lymphocyte number and function (afferent limb) and cytokine production and action on monocytes and macrophages (efferent limb). The methods used with and the utility of the present invention can be shown by the following non-limiting examples and accompanying figures.
- Methods:
- General Methods in Immunology:
- Standard methods in immunology known in the art and not specifically described are generally followed as in Stites et al. (eds), Basic and Clinical Immunology (8th Edition), Appleton & Lange, Norwalk, Conn. (1994) and Mishell and Shiigi (eds), Selected Methods in Cellular Immunology, W.H. Freeman and Co., New York (1980). Immunoassays: In general, ELISAs are one immunoassays employed to assess a specimen as needed. ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate other immunoassays, such as radioimmunoassays (RIA) can be used as are known to those in the art. Available immunoassays are extensively described in the patent and scientific literature. See, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,,521 as well as Sambrook et al,Molecular Cloning: A Laboratory Manual, Cold Springs Harbor, New York, 1989.
- Skin Tests
- Intracutaneous skin tests are performed and evaluated as is generally known in the art. Briefly, sterile test solutions are prepared and administer generally using 25- or 27-gauge needles. The largest dimensions of both erythema and induration are measured with a ruler, in the method of the present invention at 24 hours. The inflammatory infiltrate that accumulates at the site and accompanying edema result in the induration of the skin and the diameter of this reaction ia an index of the response. Induration of 5 mm or more in diameter is the generally accepted criterion of a positive response, strong positive (major) responses can be grater than 1 centimeter. In general a negative reaction will provide a response similar to the control (no antigen) site.
- Preparation of Natural Cytokine Mixture (NCM)
- The buffy coat white cells of human blood from multiple HIV-negative hepatitis virus-negative donors is collected. In an alternative embodiment, animals are the cell source for veterinary uses. The cells from the donors are pooled and layered on ficoll hypaque gradients (Pharmacia) to yield lymphocytes free of neutrophils and erythrocytes. (U.S. Pat. Nos. 4,390,623 and 4,448,879) Alternative methods are used that would result in the same starting lymphocyte population as are known in the art.
- The lymphocytes are washed and distributed in X vivo-10 media (Whittaker Bioproducts) to flasks (MicroCELLector™ T-25 Cell Culture Flasks) in which are immobilized stimulants, i.e. mitogens, and in a preferred embodiment of the present invention PHA. However, Cibcabavakub A (ConA), pokeweed antigen (PWA) or OKT-3 can be used. Alternatively, X vivo-15 and X vivo-20 media can be used. The immobilization process for the stimulants is as described by the manufacturer for immobilizing various substances for panning procedures, i.e. separating cells, in the flasks.
- The cells are incubated for 24-48 hours in X vivo-10 media with 80 μg/ml ciprofloxacin (Miles Lab) at 37° in a CO2/air incubator. Alternatively, RPMI 1640 media is used (Webb et al. 1973). Generally the HSA is used at 0.1 to 0.5% (weight by volume). Following incubation the supernatants are poured off and collected. Human serum albumin (HSA) can be added to stabilize further the interleukins. The supernatants are stored at 4° C. to −70° C.
- Characterization of Supernatants
- The pooled supernatants are characterized by measuring the cytokine content by bioassay for IL-2 and ELISAs for the remaining interleukins IL-1-IL-15, CSFs, TNFs, and IFNs. Specifically, the following assays and kits are used in a preferred embodiment: INF-γ ELISA (ENDOGEN), IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, GM-CSF, G-CSF and TNF-A ELISAs (R&D Systems). The IL-2 bioassay is by the method of Gillis et al. (Gillis et al. “T Cell Growth Factor: Parameters of Production and a Quantitive Microassay for Activity”J. Immunol., 120:2027-2032, 1978) and is expressed as units/ml compared to a known standard of IL-2 (Schiapparelli Biosystems, Inc., Fairfield, N.J.). Sterility is tested by culture in thioglycolate broth and endotoxin measured by limulus lysate assay as is known in the art.
- Standardization of Supernatant for Cytokine Content
- Each supernatant is standardized for IL-2 content either by concentration or amount administered. In general for skin tests, the NCM is standardized to have an equivalence of 15 Units of IL-2 by bioassay in 0.1 ml of the supernatant.
- Removal of Contaminants from Supernatant
- DNA and virus exclusion, when used, employ such techniques as ultrafiltration, column chromatography, virasol, ethanol fractionation, polyethylene glycol/bentonite precipitation, gamma irradiation, and/or solvent/detergent treatment as has been used for intravenous gamma globulin and monoclonal antibodies (e.g. IGIV News Update brochure).
- Skin tests with PHA (0.5 or 1.0 μg) were performed in ten patients with H&N SCC and twenty-three Taxol-treated patients with breast cancer and nine healthy controls. Sixty-seven percent of cancer patients (14/21) did not respond to the 0.5 μg dose of PHA and had mean lymphocyte counts of 1257±167. Forty-seven percent of the cancer patients (15/33) did not respond to the 1.0 μg dose of PHA and had mean lymphocyte counts of 1383±214. The responders (7/12 & 18/33) had lymphocytes, respectively, of 2095±354 and 1755±219. All of the controls responded and had a mean lymphocyte count of 2107±285. Failure to respond to the PHA, particularly the 0.5 μg dose, is thus common in the cancer patients and reflects published anergy figures for DNCB. While patients anergic to PHA show significantly lower lymphocyte counts, the correlation of the two (FIG. 1) is not high, reflecting the fact that the defects of anergy and lymphocytopenia are related but are not obviously cause and effect.
- H&N SCC patients were analyzed for PHA and NCM skin tests and lymphocyte counts and little or no correlations were observed (FIGS. 2, 4). These data indicate that each test is looking at a different component of the CMI/DTH defects in H&N SC cancer as would be expected:
- 1) T-lymphocyte counts reflect T-lymphocyte number and indirectly the pool size;
- 2) PHA skin test responses reflects the ability of these T-lymphocytes which are present to react to PHA and to release cytokines like IL-2, IFN K, etc. and induce a monocyte/macrophage infiltration leading to the DTH dermal reaction, and
- 3) the NCM (mitogen-stimulated natural cytokine mixture) reflects the ability of preformed T-cell cytokines to induce the monocyte/macrophage accumulation characteristic of the efferent limb response.
- Thirty-three patients with locally advanced H&N SC cancers were skin tested with intracutaneous i.e. injections of NCM prior to immunotherapy with NCM in the immunotherapy strategy (Hadden et al., 1994 ibid). Twenty-five patients were NCM-positive and eight were negative to the NCM skin test read at 24 hours. Of the twenty-five, fifteen NCM positive patients had major clinical responses and eleven had minor or no response; of the eight NCM negative patients, none had major responses (TABLE 2).
- Of the major responders in the NCM+ group, only one recurrence with death (7%) has occurred and of the NCM− group, four recurrences with death (50%) had occurred. Thus, the NCM skin test is a significant and reliable predictor of clinical response to this immunotherapy protocol unexpectedly based on previous results. (FIGS.2-4).
- Of the twenty-five NCM+ patients on protocol, eight were lymphocytopenic (<1500 mm3) with a mean count of 1247±92. All but one of these patients showed an increase in lymphocytes to a mean of 1866±172 (p<0.01 by paired student T-test). Of the eight NCM negative patients, five were lymphocytopenic (mean 1391±37) and only one showed an increase by Chi square analysis (TABLE 3). Thus, the NCM skin test also predicts the immunorestorative effect of NCM on patients with low lymphocyte counts.
- In one patient treated with immunotherapy, NCM has been associated with an increase in the PHA skin test. In the three patients, NCM therapy has been associated with an increase in the NCM skin test. Thus, these parameters reflect the effect of immunotherapy. (FIG. 3)
- The advantages of this diagnostic approach are its simplicity and cost making the test widely employable, particularly in office practice, rural settings and nondeveloped countries where more complicated tests are not available or not economically feasible to use. The advantage of this approach in monitoring the impact of immunotherapy is unique in that no test or tests have emerged which can consistently monitor any immunotherapy. The combination of these three tests of the present invention therefore are useful for monitoring immunotherapies such as NCM therapy for monitoring which correct T-lymphocyte number and function and/or monocyte/macrophage function.
- Throughout this application, various publications, including United States patents, are referenced by author, citation and year and patents by number. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
- The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.
- Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.
TABLE 1 SECONDARY CELLULAR IMMUNE DEFICIENCY HIV AGING VIRAL INFECTIONS (TRANSITORY) ZINC/ ? SELENIUM DEFICIENCY BURNS/TRAUMA/SEPSIS PROTEIN CALORIE MALNUTRITION CHRONIC INFECTION/PARASITOSIS IMMUNOTOXICANTS RHEUMATOID ARTHRITIS IMMUNOSUPRESSIVE CHEMOTHERAPY -
TABLE 2 Skin Test Major Minor Chi Result Response Response Total Square NCM+ 15 10 25 χ2 = 6.6 NCM− 0 8 8 p < 0.01 Totals 15 18 33 -
TABLE 3 8 1 9 χ2 = 4.0 1 4 5 p < 0.05 9 5 14
Claims (20)
1. A method for monitoring the effect of immunotherapy in a patient undergoing immunotherapy including the steps of
administering an intracutaneous skin test with a mitogen and reading the skin test after twenty-four hours; and
administering an intracutaneous skin test with a natural cytokine mixture (NCM) and reading the skin test after twenty-four hours;
wherein patients who respond to the intracutaneous skin test correlate with positive clinical response to immunotherapy.
2. The method as set forth in claim 1 wherein said mitogen is phytohemagglutinin (PHA).
3. The method as set forth in claim 2 wherein the phytohemagglutinin is administered between the range of 0.5 to 1.0 μg.
4. The method as set forth in claim 1 wherein said mitogen is concanavalin A.
5. The method as set forth in claim 1 wherein said mitogen is pokeweed antigen.
6. The method as set forth in claim 1 wherein said NCM is administered at a dose of 0.1 ml which has an equivalence to 15 units of IL-2 by bioassay.
7. The method as set forth in claim 1 including the step of performing a white blood cell count and determining percent lymphocytes wherein a lymphocyte counts of <1500 mm3 indicate a T-lymphocytopenia.
8. A kit for the performance of the method set forth in claim 1 including a mitogen selected from the group consisting of phytohemagglutinin, concanavalin A, pokeweed antigen and said natural cytokine mixture.
9. A method to analyze cell mediated immunity in a patient needing such an analysis including the steps of
administering an intracutaneous skin test with a mitogen and reading the skin test after twenty-four hours; and
administering an intracutaneous skin test with a natural cytokine mixture (NCM) and reading the skin test after twenty-four hours;
performing a white blood cell count and determining percent lymphocytes
wherein a lymphocyte counts of <1500 mm3 indicate a T-lymphocytopenia and patients who respond positively to the PHA intracutanecus skin tests have a functional afferent immune system response and patients who respond positively to the NCM intracutaneous skin tests have a functional efferent immune system response such that the functionality of the T-cells that are present can be determined.
10. The method as set forth in claim 9 wherein said mitogen is phytohemagglutinin (PHA).
11. The method as set forth in claim 10 wherein the phytohemagglutinin is administered between the range of 0.5 to 1.0 μg.
12. The method as set forth in claim 9 wherein said mitogen is concanavalin A.
13. The method as set forth in claim 9 wherein said mitogen is pokeweed antigen.
14. The method as set forth in claim 9 wherein said NCM is administered at a dose of 0.1 ml which has an equivalence to 15 units of IL-2 by bioassay.
15. A method for selecting candidates for immunotherapy among patients who need immunotherapy including the steps of
administering an intracutaneous skin test with a mitogen and reading the skin test after twenty-four hours; and
administering an intracutaneous skin test with a natural cytokine mixture (NCM) and reading the skin test after twenty-four hours;
wherein patients who respond to both of the intracutaneous skin tests are candidates for immunotherapy.
16. The method as set forth in claim 15 wherein said mitogen is phytohemagglutinin (PHA).
17. The method as set forth in claim 16 wherein the phytohemagglutinin is administered between the range of 0.5 to 1.0 μg.
18. The method as set forth in claim 15 wherein said mitogen is concanavalin A.
19. The method as set forth in claim 15 wherein said mitogen is pokeweed antigen.
20. The method as set forth in claim 15 wherein said NCM is administered at a dose of 0.1 ml which has an equivalence to 15 units of IL-2 by bioassay.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/137,769 US20020159953A1 (en) | 1997-10-17 | 2002-05-02 | Method to diagnose and monitor cellular immune deficiencies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6232297P | 1997-10-17 | 1997-10-17 | |
US09/529,566 US6482389B1 (en) | 1997-10-17 | 1998-10-16 | Method to diagnose and monitor cellular immune deficiencies |
US10/137,769 US20020159953A1 (en) | 1997-10-17 | 2002-05-02 | Method to diagnose and monitor cellular immune deficiencies |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/021915 Division WO1999020788A1 (en) | 1997-10-17 | 1998-10-16 | Method to diagnose and monitor cellular immune deficiencies |
US09/529,566 Division US6482389B1 (en) | 1997-10-17 | 1998-10-16 | Method to diagnose and monitor cellular immune deficiencies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020159953A1 true US20020159953A1 (en) | 2002-10-31 |
Family
ID=22041732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/529,566 Expired - Lifetime US6482389B1 (en) | 1997-10-17 | 1998-10-16 | Method to diagnose and monitor cellular immune deficiencies |
US10/137,769 Abandoned US20020159953A1 (en) | 1997-10-17 | 2002-05-02 | Method to diagnose and monitor cellular immune deficiencies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/529,566 Expired - Lifetime US6482389B1 (en) | 1997-10-17 | 1998-10-16 | Method to diagnose and monitor cellular immune deficiencies |
Country Status (6)
Country | Link |
---|---|
US (2) | US6482389B1 (en) |
EP (1) | EP1027453A4 (en) |
AU (1) | AU748467B2 (en) |
CA (1) | CA2307345A1 (en) |
MX (1) | MXPA00003705A (en) |
WO (1) | WO1999020788A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050152874A1 (en) * | 2000-10-27 | 2005-07-14 | Hadden John W. | Vaccine immunotherapy for immune suppressed patients |
US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
US8591956B2 (en) | 2007-11-28 | 2013-11-26 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070031372A1 (en) * | 2004-08-05 | 2007-02-08 | Hadden John W | Vaccine immunotherapy for immune suppressed patients |
CN113289149B (en) * | 2021-05-28 | 2022-08-19 | 鹰潭荣嘉集团医疗器械实业有限公司 | Medical syringe |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
SU1654748A1 (en) * | 1989-03-16 | 1991-06-07 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Method for determination of immuno-defficiency states |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
CA2205430C (en) * | 1994-11-17 | 2001-09-04 | University Of South Florida | Method for making a medicament for treating secondary immunodeficiency |
US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
-
1998
- 1998-10-16 US US09/529,566 patent/US6482389B1/en not_active Expired - Lifetime
- 1998-10-16 EP EP98952340A patent/EP1027453A4/en not_active Withdrawn
- 1998-10-16 MX MXPA00003705A patent/MXPA00003705A/en unknown
- 1998-10-16 CA CA002307345A patent/CA2307345A1/en not_active Abandoned
- 1998-10-16 AU AU98065/98A patent/AU748467B2/en not_active Ceased
- 1998-10-16 WO PCT/US1998/021915 patent/WO1999020788A1/en active IP Right Grant
-
2002
- 2002-05-02 US US10/137,769 patent/US20020159953A1/en not_active Abandoned
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9789172B2 (en) | 2000-10-27 | 2017-10-17 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating lymphoma in immune suppressed patients |
US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
US20100047205A1 (en) * | 2000-10-27 | 2010-02-25 | Hadden John W | Vaccine immunotherapy |
US8784796B2 (en) | 2000-10-27 | 2014-07-22 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating hepatocellular cancer in immune suppressed patients |
US9789173B2 (en) | 2000-10-27 | 2017-10-17 | Irx Therapeutics, Inc. | Vaccine immunotherapy for treating cervical cancer in immune suppressed patients |
US9492519B2 (en) | 2000-10-27 | 2016-11-15 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9492517B2 (en) | 2000-10-27 | 2016-11-15 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US20050152874A1 (en) * | 2000-10-27 | 2005-07-14 | Hadden John W. | Vaccine immunotherapy for immune suppressed patients |
US8591956B2 (en) | 2007-11-28 | 2013-11-26 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9566331B2 (en) | 2009-05-15 | 2017-02-14 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
US9931378B2 (en) | 2009-12-08 | 2018-04-03 | Irx Therapeutics, Inc. | Method of immunotherapy for treatment of human papillomavirus infection |
Also Published As
Publication number | Publication date |
---|---|
AU748467B2 (en) | 2002-06-06 |
US6482389B1 (en) | 2002-11-19 |
AU9806598A (en) | 1999-05-10 |
MXPA00003705A (en) | 2002-04-17 |
EP1027453A4 (en) | 2004-12-01 |
CA2307345A1 (en) | 1999-04-29 |
EP1027453A1 (en) | 2000-08-16 |
WO1999020788A1 (en) | 1999-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Golub et al. | Correlation of in vivo and in vitro assays of immunocompetence in cancer patients | |
Slight‐Webb et al. | Autoantibody‐positive healthy individuals display unique immune profiles that may regulate autoimmunity | |
Özenci et al. | Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-α)-and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-β) treatment | |
Cannon et al. | Interleukin-1b in human plasma: Optimization of bloodcollection, plasma extraction and radioimmunoassay methods | |
Elliott et al. | Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. | |
Mawle et al. | Immune responses associated with chronic fatigue syndrome: a case-control study | |
Barlow | T lymphocytes and immunosuppression in the burned patient: a review | |
Giunti et al. | Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS | |
Bikker et al. | Increased expression of interleukin‐7 in labial salivary glands of patients with primary Sjögren's syndrome correlates with increased inflammation | |
Navikas et al. | Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis | |
Kondratenko et al. | Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells | |
AU705820B2 (en) | Methods of identifying patients having an altered immune status | |
Shibata et al. | In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in connection with its high level in tumor-bearing mice | |
Doherty et al. | Effect of a recent injection of purified protein derivative on diagnostic tests for tuberculosis in cattle infected with Mycobacterium bovis | |
Navikas et al. | Increased levels of interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta (TGF-β) mRNA expressing blood mononuclear cells in human HIV infection | |
JPS63502695A (en) | In vitro assay for detection of cellular immune response | |
US6482389B1 (en) | Method to diagnose and monitor cellular immune deficiencies | |
Luster et al. | Cell-mediated immunity and its application in toxicology. | |
Lucchesi et al. | Impaired Interleukin‐27–Mediated Control of CD 4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjögren's Syndrome | |
Liao et al. | Increased urine interleukin-1 levels in aging | |
Boetcher et al. | Brief communication: Mouse mononuclear cell chemotaxis: Description of system | |
CN116559464A (en) | Immune response assessment system | |
Cahill et al. | Circulating factors in trauma plasma activate specific human immune cell subsets | |
Wang et al. | Characterization of human peripheral blood γδ T cells in patients with sepsis | |
Urba et al. | Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTH FLORIDA, THE, FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HADDEN, JOHN W.;REEL/FRAME:013142/0412 Effective date: 20020703 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |